Everything below concerns synthetic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In captivity, these are not picky fish; They readily feed on different types of frozen, freeze-dried and live foods, such as tubifex worms, bean beetles (and larvae), bloodworms, brine shrimp, daphnia, flour beetles, krill, springtails, small or finely-chopped earthworms, black soldier fly larvae and cultured wingless fruit flies (Drosophila melanogaster). In particular, the tubifex worms and fruit flies are high in protein and nutrients, resulting in highly significant growth. A predominantly live food diet also provides nutrients for better reproductive performance. Ultimately, food variety is key, for health, but also for mimicking natural feeding habits. It was first described by Ferdinand Schultze in a catalog of specimens at the Zoological Museum of the Royal University of Berlin, published by Hinrich Lichtenstein in 1823. First import to Europe (Germany) by C.Ziggelkow, Hamburg in 1909 The genome of the angelfish was sequenced and assembled in 2022 by Indeever Madireddy, a high school student.
==== MeSH D13.695.578 – polynucleotides ==== MeSH D13.695.578.424 – oligonucleotides MeSH D13.695.578.424.224 – aptamers, nucleotide MeSH D13.695.578.424.450 – oligodeoxyribonucleotides MeSH D13.695.578.424.450.275 – DNA primers MeSH D13.695.578.424.480 – oligonucleotides, antisense MeSH D13.695.578.424.480.640 – oligodeoxyribonucleotides, antisense MeSH D13.695.578.424.480.645 – oligoribonucleotides, antisense MeSH D13.695.578.424.500 – oligoribonucleotides MeSH D13.695.578.424.600 – pyrimidine dimers MeSH D13.695.578.500 – polydeoxyribonucleotides MeSH D13.695.578.500.050 – apurinic acid MeSH D13.695.578.500.300 – poly da-dt MeSH D13.695.578.500.600 – poly t MeSH D13.695.578.550 – polyribonucleotides MeSH D13.695.578.550.050 – apurinic acid MeSH D13.695.578.550.500 – poly a MeSH D13.695.578.550.500.510 – poly a-u MeSH D13.695.578.550.530 – poly adenosine diphosphate ribose MeSH D13.695.578.550.560 – poly c MeSH D13.695.578.550.560.600 – poly i-c MeSH D13.695.578.550.600 – poly g MeSH D13.695.578.550.650 – poly i MeSH D13.695.578.550.650.600 – poly i-c MeSH D13.695.578.550.750 – poly u MeSH D13.695.578.550.750.510 – poly a-u
== Personal life == He married Margaret (Jennie) Jenkins and had two sons, Paul and Simon. Following the death in 1976 of his son Paul, guitarist with the band Free and later with Back Street Crawler, Kossoff established the Paul Kossoff Foundation which aimed to present the realities of drug addiction to children. Kossoff spent the remainder of his life campaigning against drugs. In the late 1970s and early 1980s, he toured with a one-man stage performance about the death of his son and its effect on the family. He died in 2005 of liver cancer at age 85. In its obituary, The Scotsman wrote that David Kossoff was "a man of deep convictions and proud of his Jewish origins".
This TV ad has been run every Christmas since its debut in December 2004 and features pictures of snow falling in places around Ireland finishing at St. James's Gate Brewery with the line: "Even at the home of the black stuff they dream of a white one". The UK commercial "noitulovE", first broadcast in October 2005, was one of the most-awarded commercials worldwide in 2006. In 2006, Diageo, owner of the Guinness brand, replaced the Michael Power campaign with the "Guinness Greatness" campaign, which they claim emphasises the "drop of greatness" in everyone, in contrast to the high-tension heroics of the Power character. Guinness's 2007 advertisement, directed by Nicolai Fuglsig and filmed in Argentina, is entitled "Tipping Point". It involves a large-scale domino chain reaction and, with a budget of £10 million, was the most expensive advertisement by the company at that point. The 2000s also saw a series of television advertisements, entitled Brilliant! in which two crudely animated Guinness brewmasters would discuss the beer, particularly the ability to drink it straight from the bottle. The two would almost always react to their discoveries with the catchphrase "Brilliant!", hence the campaign's title. In 2009, the To Arthur advertisement, which started with two friends realising the company's long history, hail each other by lifting up their glasses and saying: "to Arthur!". The hailing slowing spread throughout the bar to the streets outside, and finally around the world.
Sources: en.wikipedia.org
As little as 1 ounce (28 g) exists at any given time throughout the Earth's crust; aside from francium-223 and francium-221, its other isotopes are entirely synthetic. The largest amount produced in the laboratory was a cluster of more than 300,000 atoms.
Alongside dame school, Thomas also took private lessons from Gwen James, an elocution teacher who had studied at drama school in London, winning several major prizes. She also taught "Dramatic Art" and "Voice Production", and would often help cast members of the Swansea Little Theatre (see below) with the parts they were playing. Thomas's parents' storytelling and dramatic talents, as well as their theatre-going interests, could also have contributed to the young Thomas's interest in performance. In October 1925, Thomas enrolled at Swansea Grammar School for boys, in Mount Pleasant, where his father taught English. There are several accounts by his teachers and fellow pupils of Thomas's time at grammar school. In June 1928, Thomas won the school's mile race, held at St. Helen's Ground; he carried a newspaper photograph of his victory with him until his death. As a pupil he shied away from the school curriculum, preferring his own choice of reading, drama activities and contributing to the school's magazine of which he became editor. Examples of plagiarised poems he published under his own name in the magazine, and in some cases more widely, have been noted by his biographers. Subsequent research has revealed the extent and virtuosity of Thomas's plagiarism, including having a poem published in the nationally read Boy's Own Paper that had been published in the same magazine 15 years before. During his final school years he began writing his distinctively original poetry in notebooks; the first poem, dated 27 April (1930), is entitled "Osiris, come to Isis".
25. Gulzar, Bio-degradation of hydrocarbons using different bacterial and fungal species. Published in international conference on biotechnology and neurosciences. CUSAT (cochin university of science and technology), 2003
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.